8 best air purifiers to combat wildfire smoke in Canada, according to professional ratings
As of Monday morning, Toronto's air quality was among the worst in the world, earning the highest rating — a 10+, Very High Risk — on the Air Quality Health Index.
On days with poor air quality, people are more likely to experience shortness of breath, difficulty breathing and coughing or wheezing — especially if they have a chronic respiratory disease like asthma or chronic obstructive pulmonary disease (COPD).
The small particles in wildfire smoke can get into your eyes and bloodstream, and if you have a heart or lung problem, you may experience problems earlier and at lower smoke levels.
According to Health Canada, using a portable air purifier that can filter fine particles is one way to protect your indoor environment from smoke pollution.
Air purifiers, also known as air cleaners, can improve indoor air quality by removing small contaminants that can harm your health.
According to the health authority, you should prioritize the following when choosing an air purifier:
Look for a device certified by the Association of Home Appliance Manufacturers (AHAM).
Choose an air purifier sized appropriately for the room you want to put it in.
Consider the clean air delivery rate (CADR) for the room size. The CADR describes how well the device reduces tobacco smoke, dust, pollen and wildfire smoke. To reduce fine particles, select a device with the highest CADR.
Choose an air purifier with a high-efficiency particulate air (HEPA) filter.
Avoid devices that produce ozone.
Not all air purifiers are made equal. Following Health Canada's recommendations, we've listed eight AHAM-certified air purifiers and included information about recommended room sizes and CADR ratings.
Room Size: 47 ft2
Tobacco Smoke CADR: 30
Dust CADR: 41
PM2.5 CADR: 35
Pollen CADR: 52
Volts / Frequency: 120V / 60Hz
Room Size: 201 ft2
Tobacco Smoke CADR: 112
Dust CADR: 112
Pollen CADR: 112
Volts / Frequency: 100V / 50Hz | 240V / 60Hz
Room Size: 140 ft2
Tobacco Smoke CADR: 90
Dust CADR: 101
PM2.5 CADR: 95
Pollen CADR: 119
Volts / Frequency: 120V / 60Hz
Room Size: 170 ft2
Tobacco Smoke CADR: 110
Dust CADR: 120
Pollen CADR: 130
Volts / Frequency: 120V / 60Hz
Room Size: 206 ft2
Tobacco Smoke CADR: 133
Dust CADR: 141
Pollen CADR: 145
Volts / Frequency: 120V / 60Hz
Room Size: 200 ft2
Tobacco Smoke CADR: 132
Dust CADR: 130
Pollen CADR: 152
Volts / Frequency: 120V / 60Hz
Room Size: 250 ft2
Tobacco Smoke CADR: 161
Dust CADR: 160
Pollen CADR: 170
Volts / Frequency: 120V / 60Hz
Room Size: 358 ft2
Tobacco Smoke CADR: 231
Dust CADR: 240
PM2.5 CADR: 236
Pollen CADR: 259
Volts / Frequency: 120V / 60Hz
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
9 hours ago
- Hamilton Spectator
Canadian pharmacies take steps to mitigate shortage of prescription painkillers
TORONTO - Canadian pharmacies say they are taking steps to mitigate a shortage of prescription painkillers and make sure patients don't go through withdrawal or physical discomfort. Earlier this month Health Canada said the drugs that are in short supply include those that contain acetaminophen with oxycodone, such as Percocet, as well as acetaminophen with codeine, for instance Tylenol 3. These medications are prescribed to treat a wide range of ailments, from root canals to chronic back pain. The federal agency's notice said the shortage is caused by increased demand and manufacturing disruptions at some of Canada's largest pharmaceutical companies. The Canadian Pharmacists Association says a significant resupply is anticipated in early August. Shelita Dattani, senior vice president of pharmacy affairs and strategic engagement at Neighbourhood Pharmacy Association of Canada, said some pharmacies are capping supplies to 30 days to ensure there is enough for all patients. Dattani, who also works as a pharmacist in Ottawa, said it's important not to abruptly discontinue access to an opioid prescribed for pain because it could result in a patient going through withdrawal. She says there are alternative medications, but going on a new opioid is not a simple switch. This report by The Canadian Press was first published July 29, 2025. Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.
Yahoo
17 hours ago
- Yahoo
Postbiotics Market worth $224.8 million by 2030- Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., July 29, 2025 /PRNewswire/ -- According to MarketsandMarkets™, The postbiotics market is estimated at USD 146.7 million in 2025 and is projected to reach USD 224.8 million by 2030, at a CAGR of 8.9%, from 2025 to 2030. The demand for postbiotics is projected to rise significantly, driven by growing consumer interest in microbiome health and the inherent limitations of probiotics and prebiotics in terms of viability and stability. Postbiotics, composed of non-living microbial cells and metabolites, offer proven health benefits without the need for live microorganisms. Their high stability under extreme processing conditions makes them ideal for a wide range of product formulations, including shelf-stable dietary supplements, functional foods, and beverages. Heat-treated bacterial strains, most notably Lactobacillus and Bifidobacterium, are widely recognized for their safety and scientifically supported benefits in gut, immune, and skin health. As consumer demand for microbiome-friendly solutions continues to grow, postbiotics are well-positioned to capture a larger share of the biotics market. Browse in-depth TOC on "postbiotics Market" 250– Tables30– Figures200– Pages Download PDF Brochure: Postbiotics in dry form to account for the fastest growth during the forecast period Postbiotic powders are versatile forms and attractive to consumers; they are expected to be the most rapidly growing during the forecast period because postbiotic powders offer a highly concentrated dose of bioactive compounds that can be easily incorporated into multiple food and drink formats such as smoothies, cereals, and snack bars-a boon for modern lifestyles with taste and convenience intact. From a manufacturing perspective, their dry, heat-stable nature makes it easy to process them without major modifications to existing equipment or product systems. In addition, the increasing disillusionment of consumers with conventional pills has made powders, gummies, and bars alternative delivery formats all the more popular. Although live probiotics may fail in such formats, postbiotics overcome this hurdle, much more so in dry form, making them the best solution for the manufacturers as well as health-conscious consumers. This combination of formulation ease, shelf stability, and growing end-user preference underlines why dry form postbiotics are expected to witness the steepest growth in future years. Cosmetics and personal care products segment to hold greater market share during the forecast period The trend of skinimalism increasingly embraces everything simple and multifunctional in skincare, thereby rapidly increasing the demand for postbiotics. Postbiotics address numerous benefits within a singular formulation. They have been introduced into cosmetics such as moisturizing creams intended to restore the hydrolipid barrier, anti-aging serums, and hair care containing agents that strengthen the scalp and improve hair condition. Coupling their multifunctionality with safety and stability makes postbiotics suitable for sensitive, acne-prone, or otherwise problematic skin. They do not pose the risk of microbial overgrowth as live probiotics do, making them ideal for products aimed at restoring the skin's natural microbiome balance. With increasing eco-awareness and health-consciousness among consumers, and as interest rises in Clean Beauty and microbiome-friendly skincare, especially into 2025, postbiotics are expected to establish themselves as the active ingredient of choice within modern beauty. The anti-inflammatory, antioxidant, and barrier-supporting qualities of postbiotics thus enhance their efficacy and safety and have driven the postbiotic to ever-rising prominence in next-generation cosmetics and personal care products. Request Sample Pages: European region to hold a significant market share in the global postbiotics market Most of the European consumers now claim to use dietary supplements, which reveals the growing trend toward preventive health and wellness. Growing consumer engagement creates a conducive environment for the postbiotic markets as people turn to scientifically validated, gut-friendly sources for postbiotics that can be easily incorporated into daily routines through supplements and functional foods. Active participation of the major regional players with respect to Associated British Foods plc (UK), can also be the reason of European postbiotic growth. In November 2023, AB Biotek Human Nutrition & Health (UK), subsidiary of ABF (UK) sealed a partnership deal with Tetra Pak (Switzerland) to come up with innovative postbiotic solutions for food & beverage, making it easy to incorporate postbiotics into mainstream products such as dairy, plant-based drinks, and snacks without any special equipment for their manufacturing. Such partnerships widen the simplicity of the formulation of products and visibility and accessibility of postbiotic-enriched offerings. With this innovation, seen by one of the dominant European players, ABF (UK), bringing postbiotics closer to consumers through the most consumed formats, public awareness is anticipated to grow quickly, and the market is expected to expand across the region. The report profiles key players such as Cargill, Incorporated (US), ADM (US), Kerry Group PLC (Ireland), dsm-firmenich (Netherlands), Associated British Foods plc (UK), BASF (Germany), Novozymes A/S, part of Novonesis Group (Denmark), International Flavors & Fragrances Inc (US), MCLS Europe B.V. (Netherlands), Phileo by Lesaffre (France), Lallemand Inc. (Canada), Sami-Sabinsa Group. (India), CJ CheilJedang Corp. (South Korea), Biotenova Sdn. Bhd. (Malaysia), and Bioprox Healthcare (France). Get 10% Free Customization on this Report: Browse Adjacent Reports @ Food and Beverage Market Research Reports & Consulting Related Reports: Functional Food Ingredients Market by Type (Probiotics, Protein & Amino Acids, Phytochemicals & Plant Extracts, Prebiotics, Omega-3 Fatty Acids, Carotenoids, Vitamins), Application, Source, Form, Health Benefits and Region - Global Forecast to 2029 Probiotics Market Size, Share, Analysis, & Growth Trends Report by Product Type (Functional Food & Beverages (FnB), Dietary Supplements, and Feed), Ingredient (Bacteria and Yeast), End User (Human and Animal), Distribution Channel and Region - Global Forecast to 2029 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets Inc.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Insight: Our Website: Source: Logo: View original content: SOURCE MarketsandMarkets
Yahoo
17 hours ago
- Yahoo
Microbix Launches QUANTDx™ Characterized Reference Materials
New Product Line Supporting Diagnostic Assay Manufacturers MISSISSAUGA, Ontario, July 29, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of QUANTDx™, a new product line of well-characterized reference materials designed to support the development and validation of diagnostic assays. QUANTDx is being launched at ADLM 2025, the conference of the Association for Diagnostic & Laboratory Medicine being held in Chicago, USA July 28-31, at which Microbix is exhibiting. The QUANTDx product line features accurately-quantified and fully-traceable reference materials that enable assay developers to establish key analytical performance metrics — such as LoD (limit of detection), Sensitivity (positive accuracy), and Specificity (negative accuracy) — that are essential for regulatory submissions and validation. The initial QUANTDx launch includes over 80 such reference materials that cover six of the most commonly tested disease panels, namely the following types of infections — fungal, human papillomaviruses, gastrointestinal, meningitis, respiratory, and sexually-transmitted. This comprehensive product line addresses a critical need within the infectious disease diagnostics industry for high-quality, reliable, and standardized reference materials. QUANTDx complements Microbix's established Quality Assessment Products (QAPs™) portfolio, which includes the industry-recognized PROCEEDx™ (RUO) and REDx™ Controls (IVD) products. Together, these product lines address a broad spectrum of quality-related needs across the diagnostic development lifecycle—from assay design, validation, and quality release through to end-user training and ongoing quality control. This holistic support reinforces Microbix's role as a trusted partner to the global diagnostics industry. Cameron Groome, CEO & President of Microbix, commented, 'The launch of QUANTDx represents a strategic expansion of our capabilities to serve assay developers and clinical laboratories. By leveraging our in-house portfolio of organisms and expertise in nucleic acid quantification, we are confident in delivering reliable and reproducible reference materials to streamline assay development and validation.' Phil Casselli, SVP of Sales and Business Development at Microbix, added, 'We are thrilled by the support we've received from prospective customers for QUANTDx. It's clear that there is strong, unmet demand for high-quality, and fully-quantified reference materials across the diagnostics industry. We believe this launch will provide Microbix with more opportunities to support assay developers, clinical labs, and manufacturers worldwide. We fully expect QUANTDx™ to drive revenue growth and expand our global customer base.' Further information about QUANTDx is available at while purchase enquiries for QUANTDx can be e-mailed to About Microbix Biosystems Biosystems Inc. creates proprietary biological products for human health, with over 120 skilled employees and revenues targeting C$ 2.0 million or more per month. It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) and reference materials (QUANTDx™) that support clinical lab proficiency-testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs or QUANTDx are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products. Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM™ for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada. Forward-Looking InformationThis news release includes 'forward-looking information,' as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of the QUANTDx product line or its relevance, Microbix's or others' products or services, business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its presentations, regulatory compliance and approvals, access and sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity or timeliness of delivery), currency exchange rates, maintaining adequate working capital or raising new capital on acceptable terms or at all, and other similar statements about anticipated future events, conditions or results that are not historical facts. These statements reflect management's current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. Microbix cautions that all forward-looking information is inherently uncertain and actual performance may be affected by many material factors, some of which are beyond its control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent Microbix's judgement as of the date of this new release, and it is under no obligation to update or alter any forward-looking information except as required by applicable law. Please visit or for recent Microbix news and filings. For further information, please contact Microbix at: Cameron Groome, CEO(905) 361-8910 Jim Currie, CFO(905) 361-8910 Deborah Honig, Investor RelationsAdelaide Capital Markets(647) 203-8793 ir@ Copyright © 2025 Microbix Biosystems Inc. Microbix®, DxTM®, Kinlytic®, PROCEEDx™, QAPs™, QUANTDx™, and REDx™ are trademarks of Microbix Biosystems in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
